Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome EGFR T790M-mediated resistance to first- and second-generation EGFR-TKIs. Third-generation EGFR-TKIs, such as osimertinib and nazartinib, are effective for patients with the EGF...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Masuzawa, Keita, Yasuda, Hiroyuki, Hamamoto, Junko, Nukaga, Shigenari, Hirano, Toshiyuki, Kawada, Ichiro, Naoki, Katsuhiko, Soejima, Kenzo, Betsuyaku, Tomoko
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2017
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739653/
https://ncbi.nlm.nih.gov/pubmed/29285266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22297
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים